Phase I Trial of Novobiocin Targets Cancer with DNA Repair Gene Alterations
A phase I trial is underway to evaluate the safety and optimal dosing of novobiocin in cancer patients with DNA repair gene alterations.
Therapeutic Area
Therapeutic area intelligence for DNA Repair Inhibition with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.